Roobol, M.J., Kerkhof, M., Schroder, F.H., et al. (2009) Prostate Cancer Mortality Reduction by Prostate Specific Antigen Based Screening Adjusted for Non-Attendance and Contamination in the European Randomized Study of Screening for Prostate Cancer (ERSPC). European Urology, 56, 584.
https://doi.org/10.1016/j.eururo.2009.07.018

has been cited by the following article:

• TITLE: PSA Screening for Prostate Cancer in Men under the Age of 65: A Review of Current Practice

  AUTHORS: Andrew H. Khalifa, Joel Z. Cornfield

  KEYWORDS: Adenocarcinoma, Adenocarcinoma of the Prostate, Aggressive Disease

  JOURNAL NAME: Open Journal of Urology, Vol.8 No.5, May 10, 2018

  ABSTRACT: Purpose: To review current practice in the use of Prostate Specific Antigen (PSA) testing and assess the overall risks and benefits of PSA testing for Adenocarcinoma of the Prostate, specifically in men under age 65, and those living with risk factors for the disease. Materials and Methods: An extensive literature review of PSA testing in various age groups was conducted with the goal being to review PSA screening trends and assess current recommendations regarding PSA Screening for Adenocarcinoma of the Prostate in various age groups, focusing on studies directed towards patients under the age of 65 and the long-term risks and benefits of PSA screening in the diagnostic algorithm. In order to reduce bias, we assessed our sources for variables such as reporting, measurement and/or selection bias. Our conclusions were then compared with current recommendations. Relevant studies with data compiled after 2004, centered around PSA screening in men under the age of 65 in general and specifically in men with risk factors for developing Adenocarcinoma of the Prostate were included. Editorials, newspaper articles and other non-scholarly and non-peer reviewed sources were automatically excluded.